Our meta-analysis showed that patients in the MS group had less delay of NAT than those in the PS group (OR, 0.17; 95% CI, 0.05–0.61; p = 0.007) (Fig. 2b). The gene discussed is BRD2; the disease is myeloid sarcoma.